Aileron Therapeutics Initiates Phase I Cancer Study of ALRN-6924 in Advanced Hematologic and Solid Malignancies with Wild Type p53
![](/46/pdcnewsitem/03/41/73/dGBNU3XR38qZYKU.jpg)
Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical companyhas announced that the first cancer patients have been dosed in a Phase I clinical trial of ALRN-6924.
ALRN-6924 is a potent and specific re-activator of wild type p53, a tumour suppressor protein that has been long referred to as “the guardian of the genome.” P53 represents one of the most sought after oncology drug targets by clinical oncologists due to its central role in preventing the initiation and progression of most liquid and solid tumours. ALRN-6924 is the first clinical drug candidate that binds equipotently and inhibits both of the p53 suppressor proteins, MDM2 and MDMX, in contrast to other p53-targeting small molecule drugs in clinical development that only inhibit MDM2.
“This clinical study represents a very ambitious undertaking for Aileron and is an exciting time for our team and collaborators. The ultimate goal of this trial is to demonstrate our ability to safely and effectively engage one of the most important targets in all of oncology, p53, and further establish the druggability of transcription factors that have been shown to be some of the most important but difficult-to-target oncogenic drivers. Per our stapled peptide platform, this study will demonstrate the first systemic administration of a cell-penetrating stapled peptide and will further establish the potential of this new class of medicines for a wide range of therapeutic areas,” said Joseph A. Yanchik III, President and CEO of Aileron Therapeutics.
“It is estimated that over 10 million people are living with a cancer that has wild type p53 signaling inactivated. Our ability to directly engage the full mechanism with ALRN-6924 could have unprecedented impact not only in treating a broad range of liquid and solid tumours that test positive for wild type p53, but our drug could also expand the efficacy of many current therapies that rely on a functional p53 pathway,” said Dr Manuel Aivado, Chief Medical Officer of Aileron Therapeutics. “With the Phase I study well underway, we expect to have a steady flow of important insights into the safety and activity of ALRN-6924 in patients throughout the year.”
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance